Team 3

Proteomics and tumour progression

Team leader : Catherine Guette

Our project

The team's objective is to decipher the molecular mechanisms of tumour progression and to identify circulating biomarkers of this tumour progression using proteomic approaches. In order to study these mechanisms from a fundamental and translational point of view, we combine the complementary skills of the team members in molecular and cellular biology, proteomics, microscopy and computational biology.

From a more fundamental point of view, we will seek to understand the mechanisms of escape from treatment-induced senescence. Our hypothesis is that certain soluble factors and their receptors produced by cancer cells play an important role in the reprogramming of sub-clones that are then selected during treatment to become more aggressive and reconstitute a heterogeneous tumour population.

From a translational point of view, we will perform spatial proteomics studies on tumour tissue sections to characterise predictive markers of tumour aggressiveness and resistance to treatment. We will also seek to link the function of these markers with their cellular compartment and their post-translational modifications.

An important criterion is the ability to detect these markers by simple blood tests, with the aim of improving diagnosis or predicting response to chemotherapy, so we will focus more specifically on secreted markers.

Institut de Cancérologie de l'Ouest
15 rue André Boquel
CS 10059
49 055 Angers Cedex 2
0033 02 41 35 29 13
catherine.guette@ico.unicancer.fr

Researcher
Catherine Guette
Daniel Pouliquen
Olivier Coqueret
François Guillonneau
Eric Lelièvre
Géraldine Leman

Clinicians
Véronique Verriele
Isabelle Valo
Pedro Raro
Anne Patsouris

Student
Hugo Coquelet

Technicians
Alice Boissard
Cécile Henry
 

2022 :

2021 :

2020 :

Fundings

Associations

• M2 :
• Thesis :
• Other :
• Feel free to contact us